In another example, bispecific CAR-NK cells targeting both CD19 and B-cell maturation antigen (BCMA) exhibited strong cytotoxic activity against B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM) in vitro, suggesting the need for further in vivo studies to validate these findings (186). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.